FDA Requests More Trial Data Related to Pfizer’s Paxlovid
The FDA has asked Pfizer for additional trial data to address concerns about the return of COVID-19 symptoms within days of an initial treatment with the company’s combination antiviral drug Paxlovid (nirmatrelvir, ritonavir).
The agency wants the company to conduct a placebo-controlled trial to evaluate a subsequent treatment course of Paxlovid and expects to see topline results by Sept. 30, 2023.
Pfizer is also expected to submit data by the same deadline from a controlled trial to evaluate different durations of Paxlovid treatment in immunocompromised patients with mild-to-moderate COVID-19.
Paxlovid is currently FDA-authorized for treatment of mild-to-moderate COVID-19 in adults and pediatric patients 12 years of age and older weighing at least 40 kg.
Upcoming Events
-
07May
-
14May
-
23May
-
30May
-
21Oct